Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone

Phase 2

Active, not recruiting

• Conditions: Metastatic Prostate Cancer; Castration-resistant Prostate Cancer; Prostatic Neoplasm; Cancer of the Prostate; Progressive mCRPC
• Interventions: Drug: I-131-1095; Drug: Enzalutamide

• Registration Number: NCT03939689
• Lead Sponsor: Progenics Pharmaceuticals, Inc.

Brief Summary

This is a multicenter, randomized, controlled, phase 2 clinical trial designed to evaluate the safety and efficacy of I-131-1095 radiotherapy in combination with enzalutamide compared to enzalutamide alone in participants with prostate-specific membrane antigen (PSMA)-avid metastatic castration resistant prostate cancer (mCRPC) who have progressed on abiraterone. Participants must be chemotherapy-naive and must be ineligible or refuse to receive taxane-based chemotherapy at time of study entry. PSMA-avidity will be determined by central imaging review based on assessment of 18F-DCFPyL PET/CT imaging during screening. Eligible participants meeting the PSMA-avidity criteria will be randomized in a 2:1 ratio to receive either I-131-1095 in combination with enzalutamide (80 participants) or enzalutamide alone (40 participants). An interim analysis for efficacy will be performed after a minimum of 48 evaluable participants have PSA data for at least three months following the first dose of randomized treatment.

All participants will be followed for efficacy, safety assessments, survival status, adverse events of special interest, and new anti-cancer therapy for at least one year or to the end of the study (whichever is later) following the first dose of randomized treatment. Safety data will be monitored by an independent Data Monitoring Committee and the sponsor.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-05-03
• Study First Submitted QC: 2019-05-06
• Study First Posted: 2019-05-07
• Study Start: 2019-05-30
• Primary Completion: 2023-09-21
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-20
• Last Update Posted: 2023-11-22
• Study Completion: 2024-09-24

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Male
• Target Recruitment: 120

Inclusion Criteria

1. Male ≥ 18 years of age

2. Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features at initial diagnosis

3. Castration-resistant prostate cancer, with serum testosterone ≤ 50 ng/dL at Screening

4. Radiographic evidence of metastatic disease prior to Randomization or up to 21 days prior to Screening

5. Disease progression on prior abiraterone therapy as defined by meeting at least one of the following criteria per the investigator:

   1. PSA progression as defined by a minimum of two rising PSA levels at least 1 week apart
   2. Soft tissue disease progression defined by RECIST 1.1
   3. Bone disease progression defined by two or more new lesions on bone scan

6. Planned to receive treatment with enzalutamide

7. Subjects who are ineligible or choose not to receive taxane-based chemotherapy based on personal preference or physician opinion. Examples of conditions that could make a patient ineligible or refuse to receive taxane-based chemotherapy, but would allow them to still be eligible to receive I-131-1095 include the following:

   1. Poor performance status
   2. Prior intolerance to cytotoxic agents
   3. History of another malignancy suspected for recurrence or metastases
   4. Other serious medical conditions such as symptomatic peripheral neuropathy CTCAE Grade 2 or higher; or clinically significant cardiovascular disease per the Investigator or treating physician

8. Subjects receiving bisphosphonate therapy must have been on stable doses for at least 4 weeks prior to Randomization

9. ECOG performance status 0-2

10. If sexually active, agree to use a medically acceptable method of birth control or sexual abstinence from the time of dosing through 28 days after the last dose of I-131-1095. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.

11. Estimated life expectancy of at least 6 months as determined by the Investigator.

12. Able and willing to provide signed informed consent and comply with protocol requirements

Exclusion Criteria

1. Received any anti-tumor therapy within 4 weeks of Randomization, with the exception of abiraterone, GnRH therapy and non-radioactive bone-targeted agents

2. Received prior chemotherapy for castration-resistant prostate cancer

3. Superscan as evidenced on baseline bone scan

4. Treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 within 6 months prior to Randomization

5. Prior hemi-body irradiation

6. Prior PSMA-targeted radioligand therapy

7. Major surgery within 4 weeks of Randomization

8. Impaired organ function as evidenced by the following laboratory values at Screening:

   1. Absolute neutrophil count < 1500 μL
   2. Platelet count < 100,000/μL
   3. Hemoglobin < 9.5 g/dL
   4. Albumin < 3.0 g/dL (30 g/L)
   5. Total bilirubin > 2 x ULN unless in instances of known or suspected Gilbert's disease
   6. AST or ALT > 2.5 x ULN
   7. Calculated creatinine clearance (CrCL) < 30 mL/min (Cockroft-Gault equation), or currently on renal dialysis.

9. QT interval corrected for heart rate (QTc) > 470 msec

10. Previous use of enzalutamide for more than 7 days prior to consent

11. Planned initiation of alternative therapy for prostate cancer, investigational therapy, or participation in clinical trials during the study

12. History or risk of seizure (i.e., clinically significant neurological disorder) or any other condition that contraindicates treatment with enzalutamide

13. Gastrointestinal disorder affecting absorption of oral medications

14. Known or suspected brain metastasis or active leptomeningeal disease

15. Active malignancy other than prostate cancer, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or non-muscle invasive bladder/urothelial cancer

16. Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completing the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
I-131-1095 in combination with enzalutamide	I-131-1095	-
Enzalutamide	Enzalutamide	-
I-131-1095 in combination with enzalutamide	Enzalutamide	-

Primary Outcome Measures

Name	Time	Method
PSA Response Rate	Up to 53 weeks	The proportion of participants with a PSA response according to PCWG3 criteria defined as the first occurrence of a 50 percent or more decline in PSA from baseline, confirmed by a second measurement at least 3 weeks later.

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	Up to 53 weeks	The proportion of participants who have a partial response (PR) or complete response (CR) based on RECIST 1.1 for soft tissue or PCWG3 for bone (PCWG3-modified RECIST 1.1).
Radiographic Progression Free Survival (rPFS)	Up to 53 weeks	Time from randomization to the first occurrence of radiographic progression based on RECIST 1.1 for soft tissue or PCWG3-modified RECIST 1.1 for bone, respectively, or unequivocal clinical progression, or death on study from any cause.
Overall Survival (OS)	Up to 5 years	Overall Survival is defined as time from randomization to death from any cause.
PSA Progression	Up to 53 weeks	Time from randomization to the date of the first PSA increase from baseline ≥ 25 percent and ≥ 2 ng/ml above nadir confirmed by a second PSA assessment defining progression ≥ 3 weeks later per PCWG3.
Duration Of Response	Up to 53 weeks	Time from the first date of complete response (CR) or partial response (PR) to the first occurrence of radiographic progression based on PCWG3-modified RECIST 1.1, or unequivocal clinical progression.
Time To Initiation Of Next Treatment For Prostate Cancer	Up to 5 years	Time from randomization to initiation of any new treatment for prostate cancer.
Incidences Of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events As Assessed by CTCAE v5.0 (Safety Outcome Measure)	After first administration of study drug to visit week 53	TEAEs will be summarized by SOC and PT using the frequency and percentage of participants experiencing any adverse event, experiencing each SOC and experiencing each PT within each SOC.
Changes In Temperature (Safety Outcome Measure)	Baseline to week 53	Percentage of patients with abnormal clinically significant changes in body temperature will be presented by treatment group and visit.
Shift From Baseline In Selected Clinical Chemistry Laboratory Values At Follow-up (Safety Outcome Measure)	Baseline to week 53	Percentage of patients with clinically significant abnormal values of potassium, sodium, magnesium, calcium (corrected) - per CTCAE5, urea and total protein - per investigator assessment will be presented by treatment group.
Shift From Baseline In Selected Hematology Laboratory Values At Follow-up (Safety Outcome Measure)	Baseline to week 53	Percentage of patients with clinically significant abnormal changes in hemoglobin, erythrocytes, thrombocytes, leukocytes, absolute neutrophil count, basophils, eosinophils and monocytes will be presented by treatment group.
Changes From Baseline In Overall Electrocardiogram (ECG) Assessment At Follow-up (Safety Outcome Measure)	Baseline and weeks 1, 9, 17, 25, 53 (131-I-1095 + enzalutamide treatment group); Baseline and week 53 (enzalutamide treatment group)	Percentage of patients with abnormal clinically significant changes on electrocardiogram (ECG) per central reviewer's assessment will be presented by treatment group.
Changes In Blood Pressure (Safety Outcome Measure)	Baseline to week 53	Percentage of patients with abnormal clinically significant changes in systolic and diastolic blood pressure will be presented by treatment group and visit.
Summary Of Concomitant Medications (Safety Outcome Measure)	Baseline to week 53 (concomitant medications); from week 54 up to 5 years (anti-cancer therapies only)	Medications will be summarized by ATC4 class and generic term using number of participants and percentages by treatment group and overall.
Adverse Events Resulting In Discontinuation Of Study Drug (Safety Outcome Measure)	After first administration of study drug to visit week 53	A high-level summary of TEAEs will be presented for participants who had at least one TEAE overall, seriousness, and leading to discontinuation of treatment.
Physical Examination Findings (Safety Outcome Measure)	At baseline and weeks 9, 17, 25, and 53	Percentage of patients with clinically significant abnormal changes on physical examination at weeks 9, 17, 25 and 53 will be presented by treatment group. Clinically significant abnormal physical examination findings will be captured in medical history if prior to study drug treatment.
Changes In Heart Rate (Safety Outcome Measure)	Baseline to week 53	Percentage of patients with abnormal clinically significant changes in heart rate will be presented by treatment group and visit.

Trial Locations

Locations (27)

Medstar Georgetown University Hospital; 🇺🇸 Washington, District of Columbia, United States

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States

City of Hope; 🇺🇸 Duarte, California, United States

University of Iowa; 🇺🇸 Iowa City, Iowa, United States

University of Virginia Cancer Center; 🇺🇸 Charlottesville, Virginia, United States

VA Palo Alto Healthcare System; 🇺🇸 Palo Alto, California, United States

Tulane Medical School; 🇺🇸 New Orleans, Louisiana, United States

LifeSpan Cancer Institute; 🇺🇸 Providence, Rhode Island, United States

The Ottawa Hospital; 🇨🇦 Ottawa, Ontario, Canada

VA Greater Los Angeles Healthcare System; 🇺🇸 Los Angeles, California, United States

Centre Hospitalier Universitaire de Sherbrooke; 🇨🇦 Sherbrooke, Quebec, Canada

UCLA; 🇺🇸 Los Angeles, California, United States

Hoag Family Cancer Institute; 🇺🇸 Newport Beach, California, United States

The University of Chicago; 🇺🇸 Chicago, Illinois, United States

University of Maryland; 🇺🇸 Baltimore, Maryland, United States

SUNY Upstate Medical University; 🇺🇸 Syracuse, New York, United States

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Virginia Mason Medical Center; 🇺🇸 Seattle, Washington, United States

University of Washington - Seattle Cancer Care Alliance; 🇺🇸 Seattle, Washington, United States

London Health Sciences Centre; 🇨🇦 Toronto, Ontario, Canada

University Health Network - Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada

University of Michigan Comprehensive Cancer Center; 🇺🇸 Ann Arbor, Michigan, United States

Centre Hospitalier Del' Universite de Montreal; 🇨🇦 Montreal, Quebec, Canada

Jewish General Hospital; 🇨🇦 Montreal, Quebec, Canada

Centre Hospitalier Universitaire de Quebec; 🇨🇦 Quebec City, Quebec, Canada

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States

University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States